The most recent trading session ended with Novo Nordisk (NVO) standing at $106.95, reflecting a -1.53% shift from the previouse trading day's closing. On the other hand, the Dow registered a loss of 0 ...

People taking Ozempic and Wegovy, which contain the drug semaglutide, may be at an increased risk of developing a ...

Novo Nordisk’s (NVO) blockbuster diabetes drug Ozempic may have a potential link with an eye condition that causes vision ...

NVO's CagriSema target of up to 25% in long-term weight loss is highly promising vs. 15% through Wegovy and 20% through ...

Over half of American adults are eligible for semaglutide, but insurance and other barriers make it hard for people to access ...

Popular GLP-1 medications like semaglutide in Ozempic and Wegovy help people lose weight, but what should patients know about ...

It’s quickly become evident that GLP-1 drugs for diabetes, weight loss, and more are the new wonder drugs—if only people ...

Novo Nordisk A/S’s blockbuster shot Ozempic was linked to an increased risk of a rare form of vision loss in a study that ...

Britons paying privately for obesity drugs are increasingly choosing Eli Lilly's Mounjaro over Novo Nordisk's Wegovy, online ...

GLP-1 agonists have taken the pharma world by storm, and Novo Nordisk has been at the forefront of it all thanks to ...

Finding a good growth stock to buy these days isn't easy. Many that have been doing well are at sky-high valuations.

A Danish court has sentenced a British hedge fund trader to 12 years in prison in connection with what authorities say was a ...